Ureaplasma urealyticum and Mycoplasma hominis are small, self-replicating prokaryotes belonging to the class Mollicutes. These organisms and others in their class have been linked to adverse pregnancy outcome. U. urealyticum and M. hominis produce phospholipase A 2 and in doing so initiate prostaglandin synthesis. 1 This activation may result in preterm labor and weakening of the fetal membranes.
Early studies linking these organisms to adverse pregnancy outcome involved vaginal and cervical cultures obtained on patients with ruptured membranes or amniotic fluid at time of cesarean section or labor. Two studies have shown these organisms to be associated with preterm rupture of the membranes and preterm labor when colonization was diagnosed at the time of genetic amniocentesis. 2, 3 Gray et al. 2 in 1992 (n ϭ 8) found a 75% incidence of spontaneous abortion, a 25% incidence of preterm birth, and a 12.5% incidence of subsequent neonatal death. In 1995, Horowitz et al. 3 demonstrated a 50% adverse pregnancy outcome with U. urealyticum or M. hominus infection as opposed to 12% adverse pregnancy outcome without this infection (n ϭ 6).
Although these reports involve a small number of patients, they led to the routine culturing of amniotic fluid obtained at the time of genetic amniocentesis at our facility. We retrospectively analyzed our experience to see whether treatment with erythromycin improved pregnancy outcome in regards to mid-trimester loss as well as third trimester complications.
MATERIALS AND METHODS
A retrospective analysis was conducted of 2718 genetic amniocentesis specimens, which were cultured for the presence of U. urealyticum and/or M. hominis at the Munroe Meyer Institute for Genetics and Rehabilitation between March 1993 and January 1997. A culture kit (MycoScreen GU; Irvine Scientific, Santa Ana, CA) was used to culture all fluid obtained for genetic diagnostic purposes. The MycoScreen GU vial was inoculated with 0.5 to 1.0 ml of amniotic fluid and then incubated at 36 to 37°C for up to 6 days. Once a color change was noted, another vial (MycoTrim GU) was subcultured to allow for identification of the organism.
Physicians caring for the patients were notified of the results by the genetics laboratory. Treatment was on the discretion of the physician after notification of the results. Length of treatment varied, but all treated patients received erythromycin, the majority for 10 days. Data collected in each case included the indication for genetic amniocentesis, gestational age at amniocentesis, karyotype, gestational age at delivery, complications of pregnancy and delivery, and any antimicrobial treatment.
Statistical analysis was performed using Epi Info, Version 6.
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Group comparisons were made using the Fisher's exact test, and p values less than 0.05 were considered statistically significant.
RESULTS
During this study period, 2718 amniotic fluid specimens were processed by the laboratory. A total of 49 specimens (1.8%) culture positive for U. urealyticum or M. hominis. Five of the patients were lost to follow-up at the time of this analysis. Therefore, information about treatment status was not available. One patient was excluded from outcome analysis that presented for amniocentesis for an elevation in maternal serum ␣-fetoprotein, but was found to have a fetal demise at 18 weeks. Amniocentesis was performed for karyotype, and the patient was informed of the positive culture after the second trimester termination had been completed. This left a total of 43 patients for statistical evaluation. The treatment group consisted of 34 patients who received oral erythromycin. Nine patients were untreated. This group included one woman who miscarried before culture results were available to allow for the option of treatment.
The indication for amniocentesis in each case was recorded at the time of submission of the amniotic fluid (Table 1 ). In the treated and untreated groups, advanced maternal age was the most common indication. The second most common indication was abnormal maternal marker screening that suggested the presence of a neural tube defect or aneuploidy.
Pregnancy outcomes were compared between the two groups ( Table 2) . Mid-trimester pregnancy loss occurred in four patients in each group with a rate of 11.4% in the treatment group and 44.4% in the untreated group ( p ϭ 0.04). Of the four losses in the treatment group, one was a recognized intrauterine death at the time of ultrasound and amniocentesis for elevated maternal serum ␣-fetoprotein, two resulted in pregnancy loss before completion of the antibiotic therapy, and the fourth was an intrauterine death diagnosed 4 weeks after amniocentesis. All had normal karyotypes. In the group not treated, all losses were within 3 weeks of amniocentesis, and all had normal karyotypes.
Preterm delivery was similar in the treated and untreated groups: 19.4% and 20%, respectively ( p ϭ 0.68). The total incidence of adverse pregnancy outcomes was 28.6% and 55.6% in the treated and untreated groups, respectively. This higher incidence in the untreated group did not reach statistical significance. In the treatment group, there were four preterm deliveries between 34 and 35 weeks, one in a twin gestation. One singleton delivery at 34 weeks was associated with chorioamnionitis. One fetus was delivered at 29 weeks secondary to severe preeclampsia and placental abruption. The final treated patient had a 28-week intrauterine death of a fetus with 47,XY,ϩ21 karyotype, cardiac malformation, and growth restriction. One fetus in the untreated group had a preterm delivery at 28 weeks associated with premature rupture of membranes, preterm labor, and chorioamnionitis. Both instances of chorioamnionitis were confirmed by pathologic evaluation of the placenta.
DISCUSSION
Mollicutes class microorganisms are distinguished by their lack of a cell wall. Although there are 150 distinct species, only 14 are known to infect humans and only U. urealyticum and M. hominis have been implicated in maternal and fetal infections.
1 M. hominis was reported to be associated with abortion by Harwick et al. 5 with 83% of patients with fever at the time of spontaneous abortion having either cultures positive for M. hominis or serologic evidence of infection. In 1980 Embree et al. 6 reported a series of patients with pregnancies complicated by infection. In a subgroup of patients with spontaneous abortion, 100% had placenta cultures positive for U. urealyticum and/or M. hominis.
We are not the first investigators to report isolation of the organisms from amniotic fluid with intact membranes and subsequent pregnancy loss. Gray et al. 2 reported a series of eight patients with positive cultures for U. urealyticum. Final pregnancy outcome revealed a 75% incidence of spontaneous abortion before 21 weeks of gestation. Of the pregnancies that delivered after 21 weeks, one delivered at 24 weeks resulting in a neonatal death and the second delivered at 30 weeks. These deliveries resulted in a prematurity rate of 25% and a 50% perinatal mortality. All placental specimens revealed chorioamnionitis, with all examined fetal lung tissue demonstrating a positive inflammatory response. Horowitz et al. 3 published a report of 129 patients undergoing mid-trimester amniocentesis, six of whom were found to have positive cultures for U. urealyticum. The rate of pregnancy loss was 16.6% (1 of 6) in the culture-positive group and 0.8% (1 of 123) in the culture-negative group. The rate of adverse pregnancy outcome (including preterm birth, fetal death, and low birth weight) was 50% (3 of 6) versus 12.2% (15 of 123) in the two groups, respectively. In the group of patients reported here, the rate of pregnancy loss was 44.4% in the group not receiving antibiotics with an additional 20% of patients delivering prematurely, for a total rate of 64.4% adverse pregnancy outcomes. This is very similar to these previous reports in which antibiotic treatment was not undertaken. Our population differs in the fact that most women received treatment with antibiotics when the physician was notified of the culture results. Two reports in the literature demonstrate success in treating positive amniotic fluid cultures with erythromycin. Romero et al. 7 reported culture-documented eradication of U. urealyticum from amniotic fluid in a patient with premature rupture of membranes after 6 days of combination antibiotic therapy using erythromycin, ampicillin, gentamicin, and clindamycin. Later, Mazor et al. 8 reported sterile amniotic fluid after a 10-day course of erythromycin alone in a patient with preterm labor and a positive culture. In this report, erythromycin was used in all treated patients. Erythromycin was thus chosen as the agent of choice, given that no other reports were available that documented eradication of the organisms.
Our data suggest that culture of amniotic fluid at genetic amniocentesis combined with treatment of positive cultures might result in improved pregnancy outcome from the perspective of mid-trimester loss. We are aware that this data may be somewhat skewed from the standpoint that some of the pregnancy losses (fetal death documented at the time of amniocentesis) occurred before culture results were obtained and before treatment could be initiated. All four losses in the untreated group occurred in karyotypically normal fetuses after the procedure. Leaving U. urealyticum and M. hominis infections as a possible explanation for pregnancy loss associated with genetic amniocentesis in these patients. Amniotic fluid specimens were analyzed at a single facility with multiple operators performing the amniocentesis. There was no attempt made to control for each operator in this retrospective analysis.
Our results are theoretically similar to those of a retrospective report by Wenstrom et al., 9 in which increases were found in interleukin-6 in amniotic fluid in women who subsequently suffered pregnancy loss. It is interesting to speculate whether vaginal/cervical cultures for this organism would reveal a high rate of colonization in these women. Until additional data are gathered, it would appear prudent to culture these areas in women with positive amniotic fluid cultures in conjunction with oral erythromycin treatment.
In conclusion, treatment of an amniotic U. urealyticum and M.
hominis infection with erythromycin was associated with an improvement of the rate of mid-trimester loss after amniocentesis performed for genetic analysis. Preterm delivery rates between the two groups were similar, which may indicate recolonization; however, there was only one pregnancy in each group with preterm labor and evidence of infection, i.e., chorioamnionitis. We feel our data is insufficient on its own to recommend routine culturing of amniotic fluid, especially given the prevalence of less than 2% of it in our patient population. Prospective studies would be needed to validate this report. A comparison between treatment and no treatment would be required to prove causal effect. Additionally, repeat amniocentesis would be required to prove eradication of the organism from the amniotic fluid, and follow-up vaginal cultures would be needed to document recolonization of the genital tract with consideration for retreatment.
